Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-12
2005-07-12
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S183000, C540S460000, C540S473000, C540S504000, C540S505000, C540S514000, C540S517000, C540S521000
Reexamination Certificate
active
06916805
ABSTRACT:
This invention discloses quinoxalinones which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts and prodrugs of the compounds, pharmaceutically acceptable compositions comprising the compounds, their salts or prodrugs, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis.
REFERENCES:
patent: 4082735 (1978-04-01), Jones et al.
patent: 4082736 (1978-04-01), Jones et al.
patent: 4870175 (1989-09-01), Suzuki et al.
patent: 63145272 (1988-06-01), None
patent: 63-301874 (1988-12-01), None
patent: 1254348 (1989-10-01), None
patent: 9707116 (1997-02-01), None
patent: 97487006 (1997-12-01), None
patent: 9801428 (1998-01-01), None
patent: WO 98/13368 (1998-04-01), None
patent: 99813368 (1998-04-01), None
Ittyerah et al., Chemical Abstracts, vol. 52:77247, 1958.
Stetter, Chemical Abstracts, vol. 48:7118, 1954.
PCT International Search Report, PCT/US98/26704, 1998.
Lappato et al., “X-ray structure of anistasin at 1.9 Å resolution and its modeled complex with blood coagulation factor Xa”,The EMBO Journal, vol. 16, No. 17, 5151-5161, 1987.
Mellott et al., “Enhancement of Recombinant Tissue Plasminogen Activator-induced Reperfusion by Recominant Tick Anticoagulant Peptide, A Selective Factor Xa Inhibitor, in a Canine Model of Femoral Arterial Thrombosis”,Fibrinolysis, 7, 1993, 195-202.
Lynch et al., “Primary Prevention of Coronary Arterial Thrombosis with the Factor Xa Inhibitor rTAP in a Canine Electrolytic Injury Model”,Thrombosis and Haemostasis, 74 (2) 640-5, 1995.
Schaffer et al., “Antithrombotic Efficacy of Recombinant Tick Anticoagulant Peptide”,Circulation, 1991, 84:1741-1748.
Fioravanti, et al., “Antithrombotic Activity of Recombinant Tick Anticoagulant Peptide and Heparin in a Rabbit Model of Venous Thrombosis”,Thrombosis Research, 71, 317-324, 1993.
Wong et al., “Antithrombotic Actions of Selective Inhibitors of Blood Coagulation Factor Xa in Rat Models of Thrombosis”,Thrombosis Research, vol. 83, No. 2, 117-126, 1996.
Edmunds and Rapundalo,Annual Reports in Medicinal Chemistry, 31, 51-60, 1996.
Kunitada and Nagahura, “Factor Xa Inhibitors”,Current Pharmaceutical Design, 1996, 2, 531-542.
Matuszczak and Mereiter, “Syntheses in the series of pyrazolyl-substituted quinoxalines”,Heterocycles, vol. 45, No. 12, 1997, 2449-2462.
Leardini et al., “Peroxydicarbonate-Mediated Oxidation of N-(ortho-Aryloxyphenyl) and N-(ortho-Arylaminophyenl)aldimines”,Tetrahedron, vol. 51, No. 44, 12143-12158, 1995.
Awad and Hassan, “Studies in Vilsmeier-Haack Reaction. Application to Quinoxalinones”,Collect. Czech. Chem. Commun.,vol. 55, 1990, 2715-2721.
Otomasu et al., “Quinoxaline 1,2-Dihydroimidazo[1,2-a]-quinoxaline 1,2-Dihyro-3H-pyrimido[1,2-a]quinoxaline”,Yakugaku Zasshi, 90 (11), 1391-1395, 1970.
Seth et al., “Studies in Antiamoebic Agents: Synthesis of Substituted Inophenazines, Azaindophenazines & Azaquinoxalines”,Indian Journal of Chemistry, vol. 12, 1974, 124-128.
Sparatore et al., “Quinolizidine Derivatives as Potential Antitumoral Agents”,II Farmaco, 44 (10), 945-950, 1989.
Hahn et al., “Effect of Mepyramine and Spasmolytic Agnets on Guinea-Pig Anaphylaxis with Special Reference to the Protracted Shock”,Arch. Int. Pharmacodyn.,199, 108-121, 1972.
Chemical Abstracts, vol. 111, No. 9, 1989, abstract 78027u.
Morrow and Regan, “Some Unusual Oxidation Reactions of 1,3-Diaryl-3,4-dihydro-7-methoxy-2(1H)-quinoxalineones”,J. Org. Chem.,vol. 36, No. 1, 1971, 27-31.
Katoh et al., “Structural Analysis of N-( -phenylalkyl)substituted quinoxaline-2(1H)-ones and -thiones”,Heterocycles, vol. 44, No. 1, 1997, 357-366.
Kurasawa et al., “Revised Structure for the Production from the Reaction of 3-Hydrazinocarbonylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxaline with Nitrous Acid”,Chem. Pharm. Bull.,32 (10), 4140-4143, 1984.
JP63301874, Dec. 8, 1998, Ito Yoshikuni et al., IPC Classifications, C07D241/44 Abstract, 1988.
Dudley Danette Andrea
Edmunds Jeremy John
Berven Heidi M.
Bott Cynthia M.
Leon Andrew J.
Raymond Richard L.
Warner-Lambert Company LLC
LandOfFree
Quinoxalinones as serine protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinoxalinones as serine protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoxalinones as serine protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3431592